Copyright
©The Author(s) 2019.
World J Gastroenterol. Sep 7, 2019; 25(33): 4985-4998
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4985
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4985
Sample (copies, number of samples n) | Measured Tm (°C) at channel | |||||
FAM | HEX | |||||
Min | Max | Mean ± SD (number of positives) | Min | Max | Mean ± SD (number of positives) | |
YIDD positive control DNA (24-2400000, n = 48) | 51.3 | 52.2 | 51.7 ± 0.2 (48, 100%) | (-) | (-) | (-) |
WT positive control DNA (24-2400000, n = 48) | (-) | (-) | (-) | 61.9 | 63.3 | 62.6 ± 0.4 (46, 95.8%) |
YIDD and WT standard mixtures (24-2400000, n = 280) | 50.1 | 52.6 | 51.5 ± 0.3 (280, 100%) | 61.9 | 64.0 | 63.0 ± 0.4 (280, 100%) |
YIDD and WT standard mixtures (24, n = 56) | 49.9 | 51.9 | 51.2 ± 0.5 (45, 80.3%) | 60.9 | 63.8 | 63.0 ± 0.5 (44, 78.6%) |
YIDD of clinical samples in duplicate (82-180000, n = 17) | 49.6 | 51.9 | 51.3 ± 0.5 | (-) | (-) | (-) |
YMDD of clinical samples in duplicate (65-13000000, n = 397) | (-) | (-) | (-) | 61.1 | 64.0 | 62.8 ± 0.3 |
- Citation: Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998
- URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4985.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i33.4985